椎-基底动脉系统短暂性脑缺血发作所致眩晕的疗效观察

目的:研究倍他司汀片在椎-基底动脉系统短暂性脑缺血发作所致眩晕治疗中的临床应用价值。方法:选择2009年11月～2011年4月.我院经彩色经颅多普勒确诊的椎-基底动脉系统短暂性脑缺血发作所致眩晕84例,按随机原则将其分为治疗组和对照组各42例。在采用常规治疗基础上,治疗组采用倍他司汀片口服,每次1片,2次/d。对照组采用丁咯地尔口服,每次150mg,2次/d,两组疗程均为2周。研究分析两组患者临床体征、脑血流图、血流变学指标、不良反应等。结果:(1)两组患者经治疗后,治疗组总有效率92.9%(39例)显著优于对照组总有效率66.7%(28例)(x~2=8.92,P<0.05)。(2)治疗组的血液流变学情况较对照组有明显改善(,P值均<0.05)。(3)治疗组治疗期间不良事件发生率7.14%(3倒)。对照组治疗期间不良事件发生率16.7%(7例),治疗组治疗期间不良事件发生率显著高于对照组。结论:倍他司汀片应用于椎-基底动脉系统短暂性脑缺血发作所致眩晕治疗,具有疗效显著.疗效稳定,安全,耐受性佳等优势,较丁咯地尔在该病治疗中具有更显著优势,值得临床推广。

The Clinical Observation of The Dizziness Caused by The Transient Cerebral Ischemia of The Vertebrobasilar System

Objective:To study the clinical value of Betahistine tablets in the vertigo treatment caused by transient ischemia of vertebral-basilar artery system.Methods:84 cases of vertigo caused by transient ischemia of vertebral-basilar artery system were selected, who were diagnosed by Color Transcranial Doppler,front November 2009 to April 2011.These cases were divided into treatment group and control group in random,each of which were 42 cases.In the conventional treatment based on treatment group Betahistine tablet, each 1,2 times / d.Control group buflomedil oral,each 150mg,2 times / d,were treated for 2,weeks.Two groups of patients with clinical signs of cerebral blood flow map,blood theology indicators,adverse reactions were analyzed.Results:(1) two groups of patients after treatment,the treatment group,the total efficiency of 92.9%(39 patients) was significantly better than the control group,the total efficiency of 66.7%(28 cases)(χ~2 = 8.92,,P<0.05).(2) the rheology of the treatment group than the control group significantly improved(,P<0.05), (3) adverse events during treatment,the incidence of 7,14%(3 cases).Control group,the incidence of adverse evens during treatment was 16.7%(7 cases),treatment group,the incidence of adverse events during treatment were significantly higher.Conclusion:Betahistine used in vertebral-basilar artery transient ischemic vertigo caused by treatment with a significant effect,efficacy and stability,safety,good tolerability advantages over buftomedil in the treatment of disease with more significant advantages and is worthy of promotion.